Exploration of Noninvasive Differential Diagnosis of Benign and Malignant Liver Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-01

Study Completion Date

2025-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To explore an effective noninvasive method for differential diagnosis of liver tumors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparing the Diagnostic Efficiencies of CEUS and EOB-MRI in Patients With High Risk of HCC

NCT04212286

Hepatocellular Cancer Liver Cirrhoses Diagnoses Disease

COMPLETED NA

Clinical Application of Quantitative Major Imaging Features of CEUS LI-RADS

NCT06590948

Liver Cancer

RECRUITING

Radiomics for Diagnosing Liver Diseases and Evaluating Progression

NCT03221049

Hepatitis B / Liver Space-occupying Lesions / Patients After Ablation

UNKNOWN

Establishment of Scoring Model for Early and Differential Diagnosis of Intrahepatic Cholangiocarcinoma

NCT05327907

Intrahepatic Cholangiocarcinoma

UNKNOWN

Utility of Ultrasound Imaging for Diagnosis of Focal Liver Lesions: A Radiomics Analysis

NCT03871140

Focal Liver Lesions Ultrasonics Intelligent Diagnosis +2 more

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A retrospective study was performed to assess the performance of certain ultrasound-based parameters, in distinguishing benign from malignant with liver biopsy as the gold standard. Demographic data, clinical information and serological data were obtained from participants who were retrospectively enrolled. Receiver operating characteristic (ROC) curve analysis was conducted, including calculation of the optimal area under the ROC curve (AUC), to assess the performance of these measures in distinguishing between benign and malignant in patients with or without chronic liver disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

with chronic liver disease

patients with hepatitis B virus, hepatitis C virus and other chronic liver disease.

with chronic liver disease

Intervention Type DIAGNOSTIC_TEST

patients with hepatitis B virus，hepatitis C virus, or other chronic liver disease

without chronic liver disease

patients without hepatitis B virus, hepatitis C virus and other chronic liver disease.

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

with chronic liver disease

patients with hepatitis B virus，hepatitis C virus, or other chronic liver disease

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

(1) age 18-70 years; (2) liver examination performed for all patients prior to US-guided liver biopsy or surgery; (3) tumor can be visualized in conventional US; (4) largest tumor sectional area saved in DICOM format for use in later analyses; (5) a histopathological diagnosis made either from US-guided liver biopsy or surgical resection; (6) suitable routine clinical and US data obtained within 7 days of the histopathological diagnosis.

Exclusion Criteria

(1) unavailable pathological diagnosis; (2) liver metastatic tumors; (3) poor quality US images; and (4) a past history of surgical resection, percutaneous local ablation, radiation, transarterial and systemic therapies or liver transplantation.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No